Goldman Sachs initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with a Neutral rating and a price target of $38.00.Analyst Navdeep ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View New Coverage

Leerink Swann Starts Sage Therapeutics (SAGE) at OutperformAugust 12, 2014 7:46 AM UPDATE: Canaccord Genuity Starts Sage Therapeutics (SAGE) at BuyAugust 12, 2014 7:45 AM JPMorgan Starts Sage Therapeutics (SAGE) at OverweightAugust 12, 2014 7:45 AM